Decoy Therapeutics Inc.
NCM: DCOYLive Quote
📈 ZcoreAI Score
Our AI model analyzes Decoy Therapeutics Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get DCOY Z-Score →About Decoy Therapeutics Inc.
Healthcare
Biotechnology
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing. Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs. The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Cambridge, Massachusetts.
📊 Fundamental Analysis
Decoy Therapeutics Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -338.3%, which indicates that capital utilization is currently under pressure.
At a current price of $5.84, DCOY currently trades near the bottom of its 52-week range (0%), indicating potential value or weakness (Range: $5.40 - $415.80).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$3.11M
Trailing P/E
--
Forward P/E
-0.30
Beta (5Y)
0.36
52W High
$415.80
52W Low
$5.40
Avg Volume
36K
Day High
Day Low